Welcome to the story of Beta Drugs Ltd, the Ludhiana-based oncology wonder that’s busy making chemo cocktails for the world while investors keep wondering why this ₹1,635 crore company doesn’t believe in paying dividends. Trading at ₹1,620 per share with a P/E of 36.1 and a ROE of 25.9%, Beta Drugs sits comfortably among the top 10 oncology players in India—basically, the Ranveer Singh of pharma: loud in numbers, quiet in payouts.
The company clocked ₹204 crore in sales this September 2025 half, with ₹23.9 crore PAT, proving once again that it can juggle global expansions, new product launches, and regulatory paperwork better than most startups juggle their coffee bills. Despite the stock dropping 11.8% in three months, Beta’s fundamentals are far from sickly—just a bit high on valuation steroids, maybe.
Its Debt-to-Equity ratio of 0.66, ROCE of 27%, and EV/EBITDA of 18.9x suggest it’s not only earning well but also flexing its operational efficiency muscle. The only catch? It’s allergic to dividends and loves reinvesting everything. No wonder analysts watch this stock like oncologists eyeing remission.
2. Introduction
If there’s one company that defines “serious about cancer,” it’s Beta Drugs Ltd. Born in the land of lassi and logistics, this pharma company decided to specialize in oncology—arguably the most complex, capital-intensive, and regulation-heavy segment in pharma. While most generic drug makers chase painkillers and antibiotics, Beta decided to fight the big C.
But this isn’t your average generic manufacturer. Over the last few years, Beta Drugs transformed from a small injectable maker into a fully integrated oncology player, producing APIs, formulations, and even running Contract Development and Manufacturing (CDMO) operations for over 50 clients, including big pharma names like Torrent, Glenmark, and Reliance Lifesciences. That’s like being the ghost producer of the pharma industry—your products are everywhere, but your name remains whispered.
The growth trajectory reads like a Bollywood script—revenues zooming from ₹51 crore in FY18 to ₹386 crore TTM FY25, and profits swelling from ₹7 crore to ₹42 crore. If CAGR were a movie, Beta Drugs would be playing the hero and the villain both—because while growth is explosive, the stock’s valuation of 7.4x book value and no dividend payout make value investors cry in slow motion.
Still, Beta Drugs doesn’t just sell chemo drugs—it’s scripting a masterclass in how midcap pharma can grow without scandal or SEBI summons.
3. Business Model – WTF Do They Even Do?
Alright, let’s decode this cancer-killing business without getting terminally bored. Beta Drugs operates across four power-packed verticals:
1. CDMO (48% of FY24 revenue) – Think of this as “onco outsourcing.” Beta makes cancer drugs for others, offering everything from formulation development to logistics. It’s the backend ghost manufacturer for 20+ top pharma companies. Revenue here grew 46% since FY22, helped by capacity expansion in lyophilized products (basically, freeze-dried chemo).
2. Domestic Branded Formulations (29%) – This is the “front stage” where Beta sells under its own brands like Canrib, Adcilib, Beedan, and Adfill. With 100+ SKUs, it’s present in every major cancer hospital—HCG, Artemis, and even government institutions. Revenue in this segment jumped 53% in two years, powered by 7 new product launches.
3. International Business (16%) – Beta exports to 46 countries and counting, with 250+ registrations already and another 350 in the pipeline. The expansion to 18 new countries between FY22–FY24 doubled the segment’s revenue.
4. API Division (7%) – The in-house backbone. Producing key oncology APIs like Azacitidine and Abiraterone ensures control over quality and cost. They filed 6 DMFs in Brazil and doubled this segment’s revenue in two years.
In short: Beta Drugs doesn’t just sell chemo—it manufactures the raw material, bottles it, sells it, and also makes it for others. It’s the full-stack oncology factory.
4. Financials Overview
Half Yearly Results (₹ crore)
Metric
H1 FY25
H1 FY24
H2 FY24
YoY %
QoQ %
Revenue
204
180
182
13.3%
12.1%
EBITDA
41
39
36
5.1%
13.9%
PAT
24
24
18
0.0%
33.3%
EPS (₹)
23.7
24.2
17.8
-2.1%
33.1%
Figures in ₹ crore. EPS calculated directly from screener data.
Commentary: Margins are holding steady around 20%, showing that even in pharma’s cutthroat price war, Beta knows how to price its poison profitably. PAT flat YoY but up QoQ shows resilience amid API cost fluctuations. For a company with ₹146 crore in debt, maintaining interest coverage above 6x is like running a marathon while carrying a chemo kit—impressive stamina.
5. Valuation Discussion – Fair Value Range
Let’s play with numbers (safely):
a) P/E Approach: EPS (FY25 TTM) = ₹41.5 Industry P/E = 31 Fair Value Range = ₹41.5 × (30–40) = ₹1,245 – ₹1,660
b) EV/EBITDA Method: EV = ₹1,658 Cr EBITDA (TTM) = ₹88 Cr (annualized from half-year) EV/EBITDA = 18.9x Fair EV/EBITDA range (15–20x) = ₹1,400 – ₹1,850
c) DCF (Simplified): Assume 20% profit growth next 3 years, discount at 12%, terminal growth 5%. Intrinsic Value ≈ ₹1,550 – ₹1,750
Educational Fair Value Range:₹1,400 – ₹1,750
Disclaimer: This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
Oh, plenty! In FY24, Beta Drugs became the first company in Asia, Africa, and Europe to start a cytotoxic suspension facility.
